Press Releases

MA, Ph.D and post-doc candidates at US universities to be supported with 1 million USD Applications on www.dompefoundation.org | Deadline December 31st, 2023

Unprecedented comprehension of the interaction between Spike and the Human Estrogen Receptor Alfa provides insights for a new generation of anti SARS-CoV-2 and pan-Coronavirus vaccines

A team of US and European researchers have released new findings in Science Advances showing how the SARS-CoV-2 Spike (S)-protein interacts with human Estrogen Receptor Alpha (ERα) in lung tissue. Data released as pre-print on bioRxiv reveals the interaction of SARS-CoV-2 (S) Spike proteins with ERα may increase the pro-coagulation activity of endothelial cells, enhancing the risk of thrombosis and shedding new light on the pathogenic mechanisms underlying SARS-CoV-2 infection and on its sex-specific differences. Additional data by the same research groups highlights the mechanism underlying some rare vaccine-associated coagulopathies, which may be prevented by small changes in the Spike sequence used to produce currently available vaccines.

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants. Raloxifene was identified as a potential COVID-19 treatment by Exscalate4CoV consortium, a multidisciplinary European center of excellence created with the aim to fighting coronavirus by combining the best supercomputing resources and artificial intelligence with state of the art experimental facilities up through clinical validation.New digital open tools for researches are now being developed with the support of the European High Performance Computing Joint Undertaking to further accelerate the drug discovery process.

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia.Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy

Manuela Leone, MD and Whitney Hauser, OD join Dompé to Drive R&D and Medical Education Strategy

- Two Phase 3 multicenter clinical trials will evaluate the safety and efficacy of cenegermin in patients with severe Sjögren's-related dry eye disease- The Eye Research Foundation in Newport Beach, California is one of more than 10 clinical trial sites in the U.S. and Europe- Dompé is partnering with the Sjögren's Foundation to elevate understanding of the condition and provide information about opportunities to participate in clinical research.

Dompé will provide access to its Exscalate AI drug discovery platform and drug discovery facilities, in exchange for milestones and royalties as part of a multi-year, multi-program strategic collaboration in fibrosis and liver-associated solid tumorsDompé farmaceutici is strategically investing in in Engitix’s $54m Series A financing co-led by existing investor Netherton Investments (a fund investing on behalf of Mike Platt) Gianluca Rossetti, Corporate Business Development Director at Dompé and Mike Platt, co-founder and Managing Director of BlueCrest Capital, to join Engitix board of directors

Phase 3 REP0220 multicenter clinical trial with 18 sites in the U.S. and Europe underway to determine whether treatment with reparixin, which inhibits the biological activity of IL-8 (CXCL-8), is effective in hospitalized patients with severe COVID-19 pneumonia Phase 2 REPAVID-19 trial results showed reparixin led to better management of respiratory distress when compared to standard of care1

The core of the project is the aggregation of health data at a national level (from laboratory data to the genetic profile of the individual patient) with the highest safety standards (cyber security and real-time active protection) for targeted public health interventions and precision medicine.The newly-created infrastructure allows the clustering of patients’ profiles and the identification of targeted therapeutic indications through secure Cloud services, which are available to healthcare facilities throughout the country.The infrastructure leverages Davinci-1’s cloud computing – Leonardo’s High Performing Computer (HPC) – and Dompé Pharmaceuticals’ Exscalate molecular library – the enabler of the European Commission’s programme for Urgent Computing, Exscalate4Cov.